In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price target of $50.00. The company’s shares opened today at $10.65.
According to TipRanks, Butler is an analyst with an average return of -8.8% and a 38.76% success rate. Butler covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, ACADIA Pharmaceuticals, and Cormedix.
Currently, the analyst consensus on GH Research is a Moderate Buy with an average price target of $47.50.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $16.78 and a one-year low of $5.70. Currently, GH Research has an average volume of 76.05K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders.
Read More on GHRS:
